STOCKHOLM, July 4, 2024 /PRNewswire/ — Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM: CALTX) (“Calliditas”) today announces that its partner Viatris Pharmaceutical Japan G.K. (“Viatris”) has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the…